Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • elivaldogene autotemcel

    - PMLiVE

    Eli Lilly and Creyon Bio enter oligonucleotide therapy partnership worth over $1bn

    The companies will aim to develop RNA-targeted drugs for a broad range of diseases

    - PMLiVE

    FDA approves two cell-based gene therapies for sickle cell disease

    Vertex/CRISPR and bluebird bio’s gene therapies have been approved to treat patients aged 12 years and older

    - PMLiVE

    bluebird bio presents positive results for inherited blood disorder gene therapies

    The company’s sickle cell disease therapy was accepted for FDA priority review earlier this year

    - PMLiVE

    bluebird bio to sell FDA priority review voucher for $103m

    The company previously sold its second voucher to Bristol Myers Squibb for $95m

    - PMLiVE

    bluebird bio’s sickle cell gene therapy accepted for FDA priority review

    The genetic disease affects approximately 100,000 people in the US

    - PMLiVE

    bluebird bio submits US application for sickle cell gene therapy

    The genetic disease affects approximately 100,000 people in the US alone

    - PMLiVE

    Sartorius signs agreement to acquire Polyplus for €2.4bn

    The deal is expected to close during the third quarter of this year

    - PMLiVE

    bluebird bio sells second FDA priority review voucher for $95m

    The company sold its first voucher to Dutch biotech Argenx for $102m

    - PMLiVE

    FDA lifts partial clinical hold on bluebird bio’s sickle cell gene therapy studies

    The company can now resume the enrolment and treatment of patients aged two to 17 years

    - PMLiVE

    bluebird bio sells Rare Pediatric Disease Priority Review Voucher

    The company was granted two PRVs upon the FDA approvals of Zynteglo and Skysona

    - PMLiVE

    bluebird bio’s Skysona approved by FDA to treat cerebral adrenoleukodystrophy

    The gene therapy was shown to slow the progression of neurologic dysfunction

    - PMLiVE

    bluebird bio’s beta-thalassaemia gene therapy receives FDA approval

    Patients with the most severe form of the blood disorder develop life-threatening anaemia and have to receive regular blood transfusions

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links